» Articles » PMID: 34114543

Cancer Incidence Projections in the United States Between 2015 and 2050

Overview
Specialty Public Health
Date 2021 Jun 11
PMID 34114543
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The number of adults entering the age groups at greatest risk for being diagnosed with cancer is increasing. Projecting cancer incidence can help the cancer control community plan and evaluate prevention strategies aimed at reducing the growing number of cancer cases.

Methods: We used data from the Surveillance, Epidemiology, and End Results Program and the US Census Bureau to estimate average, annual, age-standardized cancer incidence rates and case counts (for all sites combined and top 22 invasive cancers) in the US for 2015 and to project cancer rates and counts to 2050. We used age, period, and cohort models to inform projections.

Results: Between 2015 and 2050, we predict the overall age-standardized incidence rate (proxy for population risk for being diagnosed with cancer) to stabilize in women (1%) and decrease in men (-9%). Cancers with the largest change in risk include a 34% reduction for lung and bronchus and a 32% increase for corpus uterine (32%). Because of the growth and aging of the US population, we predict that the annual number of cancer cases will increase 49%, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years. Cancers with the largest projected absolute increase include female breast, colon and rectum, and prostate.

Discussion: By 2050, we predict the total number of incident cases to increase by almost 50% as a result of the growth and aging of the US population. A greater emphasis on cancer risk reduction is needed to counter these trends.

Citing Articles

Alchemy in Nature: The Role of Extract Choice in Crafting Potent Anticancer Metal Nanoparticles.

El-Fitiany R, El Nahas R, Al Balkhi S, Aljaeedi S, Alblooshi A, Hassan F ACS Appl Mater Interfaces. 2025; 17(3):4637-4661.

PMID: 39798120 PMC: 11759054. DOI: 10.1021/acsami.4c19585.


Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: a mathematical modeling study.

Kim A, Cong Z, Jazieh A, Church T, Reichert H, Nicholson G BMC Health Serv Res. 2024; 24(1):1584.

PMID: 39695574 PMC: 11653844. DOI: 10.1186/s12913-024-12037-1.


Compassionate engagement of communities in support of palliative and end-of-life care: challenges in post-pandemic era.

Vitorino J, Duarte B, Ali A, Laranjeira C Front Med (Lausanne). 2024; 11:1489299.

PMID: 39493715 PMC: 11527659. DOI: 10.3389/fmed.2024.1489299.


Editorial: Revolutionizing cancer care: the promise of liquid biopsy assays for healthcare equity.

Brenner C, Fang C Front Oncol. 2024; 14:1493833.

PMID: 39493457 PMC: 11527784. DOI: 10.3389/fonc.2024.1493833.


Biogenic synthesis and physicochemical characterization of metal nanoparticles based on Calotropis procera as promising sustainable materials against skin cancer.

El-Fitiany R, Alblooshi A, Samadi A, Khasawneh M Sci Rep. 2024; 14(1):25154.

PMID: 39448765 PMC: 11502920. DOI: 10.1038/s41598-024-76422-w.


References
1.
Weir H, Anderson R, Coleman King S, Soman A, Thompson T, Hong Y . Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969-2020. Prev Chronic Dis. 2016; 13:E157. PMC: 5127176. DOI: 10.5888/pcd13.160211. View

2.
White M, Holman D, Boehm J, Peipins L, Grossman M, Henley S . Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014; 46(3 Suppl 1):S7-15. PMC: 4544764. DOI: 10.1016/j.amepre.2013.10.029. View

3.
Mariotto A, Enewold L, Zhao J, Zeruto C, Yabroff K . Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020; 29(7):1304-1312. PMC: 9514601. DOI: 10.1158/1055-9965.EPI-19-1534. View

4.
Alcaraz K, Wiedt T, Daniels E, Yabroff K, Guerra C, Wender R . Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy. CA Cancer J Clin. 2019; 70(1):31-46. DOI: 10.3322/caac.21586. View

5.
Pyron T, Fonseka J, Young M, Zimmerman L, Moore A, Hayes N . Examining comprehensive cancer control partnerships, plans, and program interventions: successes and lessons learned from a utilization-focused evaluation. Cancer Causes Control. 2018; 29(12):1163-1171. PMC: 7890469. DOI: 10.1007/s10552-018-1113-1. View